Total Revenue

Virtually unchanged (from $3.058M in Q3 2023 to $3.060M in Q3 2024)

Stable total revenue resulted from offsetting movements where a moderate increase in cosmetic ingredient sales was balanced by a decline in pharmaceuticals, echoing prior periods where shifts in product mix maintained overall revenue levels. "

Cosmetic Ingredients

+8% increase (from $1.197M to $1.290M)

The 8% increase reflects a continued recovery in demand—particularly in China—and reduced competitive pressure compared to earlier periods, though the growth is less dramatic than the 84% surge seen in Q2 2024. " "

Pharmaceuticals

–6% decline (from $1.196M to $1.122M)

A 6% decline is likely due to ongoing challenges in maintaining consistent ordering and an unfavorable shift in the product mix, which contrasts with earlier periods that had mixed recoveries in pharmaceutical sales. " "

Net Income

+38% increase (from $626,756 to $865,484)

The 38% surge in net income builds on improved operating efficiencies noted in prior periods, driven by a higher contribution from high-margin cosmetic ingredients and controlled expenses, signaling solid recovery compared to previous declines. " "

Earnings per Share (EPS)

+36% increase (from $0.14 to $0.19)

EPS improved by 36% as a consequence of the robust net income growth and improved cost structure, which continued the positive momentum established in earlier turns around and reflected in related operating income improvements. " "

Operating Income

+31% increase (from $721,872 to $949,128)

The 31% increase in operating income was driven by a 28% rise in net sales and an improved cost structure—especially through an increased proportion of high-margin cosmetic ingredients—mirroring strategies that began to reverse previous period underperformance. " "